Integrating Genomics and Neuromarkers for the Era of Brain-Related Personalized Medicine
- 8 May 2007
- journal article
- Published by Informa UK Limited in Personalized Medicine
- Vol. 4 (2), 201-215
- https://doi.org/10.2217/17410541.4.2.201
Abstract
The harsh reality is that many medical treatments do not work as expected in a significant percentage of patients, and occasionally there are serious side effects. A new paradigm of personalized medicine is emerging, which proactively tailors treatment to each individual's biological and psychological profile. The first proof-of-concept phase of personalized medicine has now been achieved. However, it has thus far focused on the use of genomic markers and on disorders of the body. The complexity of the brain is likely to require a shift from a single genetic marker focus to a more integrated approach in which additional brain-related information (neuromarkers) is taken into account. Codevelopment of genomic neuromarkers with new compounds in a personalized medicine approach will lead to increased drug R&D and treatment benefits. The emerging genomic neuromarker potential has begun to be incorporated into the template for the next version of the Diagnostic and Statistical Manual (DSM-V). The statistical power of large subject numbers in databases in general (and standardized databases in particular) provides an ideal source for elucidating the best genomic-neuromarker profiles (explaining most of the main-effects variance), which will empower a brain-related personalized medicine into mainstream clinical practice.Keywords
This publication has 48 references indexed in Scilit:
- Association of the DAT1 polymorphism with attention deficit hyperactivity disorder (ADHD): A family‐based approachAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Gefitinib in non-small cell lung cancerExpert Opinion on Pharmacotherapy, 2005
- Resting EEG theta activity predicts cognitive performance in attention-deficit hyperactivity disorderPediatric Neurology, 2005
- BDNF Variation and Mood Disorders: A Novel Functional Promoter Polymorphism and Val66Met are Associated with Anxiety but Have Opposing EffectsNeuropsychopharmacology, 2005
- “Gamma Synchrony” in First-Episode Schizophrenia: A Disorder of Temporal Connectivity?American Journal of Psychiatry, 2005
- Perception of facial expressions of emotion in bipolar disorderBipolar Disorders, 2004
- Use of haplotype information to test involvement of the LRP gene in Alzheimer's disease in the French populationEuropean Journal of Human Genetics, 2001
- Patterns of Brain Activation in People at Risk for Alzheimer's DiseaseNew England Journal of Medicine, 2000
- Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): Association of the high-enzyme activity val allele with adhd impulsive-hyperactive phenotypeAmerican Journal of Medical Genetics, 1999